BiotechTube
Avidicure

Avidicure

Leiden, Netherlands· Est.
avidicure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Avidicure is a private, preclinical-stage biotech developing a first-in-class antibody modality designed to deliver three synergistic activation signals to immune cells, a feature lacking in current antibody therapies. The company's proprietary 'Actibody' platform aims to create potent, durable, and safe monotherapies for oncology and autoimmune diseases by fully engaging both innate and adaptive immunity. Backed by top-tier investors including EQT Life Sciences and BioGeneration Ventures, Avidicure is advancing its lead γδ T cell-targeting program for hematologic and solid tumors while leveraging its platform for broad therapeutic potential.

OncologyAutoimmune Diseases

Technology Platform

Proprietary 'Actibody' platform: a human IgG scaffold genetically fused with two proprietary domains to create triple-agonistic antibodies that deliver Signal 1 (activation), Signal 2 (co-stimulation), and Signal 3 (cytokine) conditionally at the target site.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The Actibody platform addresses a core limitation in current immunotherapies by delivering complete immune activation, potentially creating best-in-class monotherapies for cold tumors and treatment-resistant cancers.
The focus on γδ T cells offers a differentiated approach in the crowded T-cell engager space, with potential advantages in safety and breadth of tumor targeting.
The platform's modularity allows for rapid expansion into new targets and indications, including autoimmune diseases, creating significant long-term value.

Risk Factors

The novel triple-agonism mechanism is unproven in humans and carries clinical risk, particularly regarding potential on-target/off-tumor toxicity and cytokine release syndrome.
The company faces intense competition from large pharma and well-funded biotechs developing advanced antibody and cell therapy modalities.
As a preclinical, private company, Avidicure is dependent on raising additional capital to fund expensive clinical development, introducing significant financing and dilution risk.

Competitive Landscape

Avidicure competes in the advanced antibody therapeutics space against companies developing bispecific/trispecific T cell engagers (e.g., Amgen, Roche, Genmab) and cytokine-armed antibodies. Its primary differentiation is the integrated delivery of three signals. In the γδ T cell niche, it faces emerging competitors like Adicet Bio, Lava Therapeutics, and GammaDelta Therapeutics, though these largely focus on bispecific engagers or cell therapies rather than triple-agonism. The platform's conditional activity is a key competitive feature aimed at improving safety over systemic agonists.

More companies in Biologics / Biosimilars →More companies in Netherlands →